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Abstract
Background: Ukrain is an anticancer drug based on the extract of the plant Chelidonium majus L.
Numerous pre-clinical and clinical investigations seem to suggest that Ukrain is pharmacologically
active and clinically effective. We wanted therefore to critically evaluate the clinical trial data in the
form of a systematic review.
Methods: Seven electronic databases were searched for all relevant randomised clinical trials.
Data were extracted and validated by both authors, tabulated and summarised narratively. The
methodological quality was assessed with the Jadad score.
Results: Seven trials met our inclusion criteria. Without exception, their findings suggest that
Ukrain has curative effects on a range of cancers. However, the methodological quality of most
studies was poor. In addition, the interpretation of several trials was impeded by other problems.
Conclusion: The data from randomised clinical trials suggest Ukrain to have potential as an
anticancer drug. However, numerous caveats prevent a positive conclusion, and independent
rigorous studies are urgently needed.
Background
Ukrain (NSC-631570) is a semi-synthetic compound
derived from the common weed, greater celandine (Cheli-
donium majus L.). This plant contains a range of alkaloids,
most notably chelidonine, also known as benzophen-
anthridine alkaloid. A leaflet distributed to patients at the
Bristol Cancer Help Centre, United Kingdom, describes
Ukrain as " the only known product, which at present
does not also destroy healthy cells, and which reduces
tumors and boosts the immune system..." [1]. Ukrain is
most commonly administered intravenously and consists
of one molecule thiophosphoric acid conjugated to three
molecules of chelidonine. It has drug licenses in several
states of the former Soviet Union.
Research on Ukrain started about 20 years ago. Mean-
while, numerous in-vitro studies [2-37] animal experi-
ments [38-83], case reports [84-97], and case series [98-
108] have emerged. Collectively, these data suggest that
Ukrain has anticancer activity in a wide range of cell lines,
which could be of clinical value. Whether or not this
translates into clinical effectiveness and whether or not
Ukrain does indeed cure some type of cancer or improves
their prognosis can best be decided on the basis of ran-
domised clinical trials (RCTs). This systematic review is
aimed at summarising and critically evaluating all such
studies.
Published: 01 July 2005
BMC Cancer 2005, 5:69 doi:10.1186/1471-2407-5-69
Received: 17 March 2005
Accepted: 01 July 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/69
© 2005 Ernst and Schmidt; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2005, 5:69 http://www.biomedcentral.com/1471-2407/5/69
Page 2 of 7
(page number not for citation purposes)
Methods
Electronic literature searches were conducted in the fol-
lowing databases: MEDLINE (1966 to date, via Pubmed),
EMBASE (1974 to date), CINAHL (Cumulative Index to
Nursing and Allied Health Literature, 1982 to date),
AMED (Allied and Complementary Medicine Database,
1985 to date), PsycINFO (1987 to date), DIMDI (Deut-
sches Institut für Medizinische Dokumentation und Infor-
mation) and The Cochrane Central Register of Controlled
Trials (CENTRAL). The following search terms were used:
'Ukrain', 'chelidonium', 'greater celandine', 'cancer', 'neo-
plasm' or 'tumour'. Further handsearches were performed
in our unit's own files as well as in the reference lists of all
located articles. The producer of Ukrain was also con-
tacted. No restrictions regarding the language of publica-
tion were imposed.
We included all RCTs of Ukrain as a treatment for any type
of human cancer. Ukrain could be used as a sole treatment
or as an adjunct to conventional therapy. Any type of
intervention was permitted in the control groups. The
clinical endpoints had to be survival or parameters indic-
ative of tumour burden. Non-randomised studies or RCTs
that did not quantify clinical endpoints were excluded
[e.g. [109-117]], as were duplicates [118].
All articles were read in full by both authors and data relat-
ing to design, diagnosis, number of subjects, treatments
for experimental and control groups, outcome measures
and results were extracted independently by both authors.
The methodological quality of each trial was assessed
using the Jadad score, unless the study was only available
in abstract form [119]. It evaluates methodological qual-
ity using three items assessing random allocation, double-
blinding and the reports of withdrawals and drop-outs
and a maximum of 5 points can be given if all criteria are
met. The authors agreed to a consensus on the assessed
data and cases of discrepancy would be settled by discus-
sion. Because of overt clinical heterogeneity, a meta-anal-
ysis was deemed unreasonable. Descriptive summaries of
the data are presented in the following text.
Results
Our search strategy identified 7 RCTs [120-126]. The
majority of these studies was published in two different
journals between 1995 and 2002 by 4 different groups of
authors from the Belarus and Germany. Key data from
these studies are summarised in Table 1 and will be dis-
cussed below.
Susak et al published an RCT in which 108 colorectal can-
cer patients received either Ukrain as a monotherapy or 5-
fluororacil for an unspecified time duration [126]. The
results suggest that this was followed by non-progression
of the malignancy in 88.8% of the patients in the experi-
mental group compared to 27.7% in the control group.
This study is only reported in abstract form. Numerous
methodological details are therefore not accessible and its
methodological quality cannot be reliably assessed.
One year later, the same research group published a simi-
lar clinical trial, this time including 96 colorectal cancer
patients [120]. Forty-eight patients received Ukrain as a
monotherapy and 48 patients received 5-fluorouracil and
radiation. The survival rate differed substantially between
the two groups. Two-year survival was 78.6% in the exper-
imental group compared to 33.3% in the control group.
This study was not blinded but applied an appropriate
method of randomisation.
Bondar et al treated 48 histologically verified rectal cancer
patients either with X-ray radiotherapy, chemotherapy
and surgery (control group) or with Ukrain and surgery
(experimental group) [121]. Before and after these treat-
ments, the authors measured 19 different laboratory
parameters including two tumour markers. In addition,
the Karnofsky Index, tumour dimensions, and recurrences
were monitored. All of these variables strongly favoured
Ukrain therapy over conventional treatment. This study
has, however, numerous limitations. For instance, the
method of randomisation was not explained; the authors
merely stated that "all patients were subdivided into two
randomised groups". Moreover, "tumour dimensions"
were mentioned as an outcome measure but neither the
methodology of measurement nor the results were pro-
vided. The recurrence rates are expressed as percentage fig-
ures and no test statistics seem to have been applied.
Uglyanitsa et al conducted a study with 28 patients suffer-
ing from bladder cancer [116] aiming "to evaluate the effi-
cacy of Ukrain". Patients were allocated to three groups
treated with a total dose of 100 (group 1), 200 (group 2),
or 300 mg Ukrain (group 3). Two weeks later tumour
regression was verified through cytoscopy and ultrasound.
Complete and partial regression was noted in 0/4 patients
of group 1, 1/4 patients of group 2, and 2/6 patients of
group 3. This study lacks many characteristics of a rigor-
ous trial; its stated aims (to evaluate efficacy) cannot be
achieved with the study design, which essentially was that
of an equivalence or dose-finding study.
Zemskov and colleagues published a "pilot study" with 42
patients suffering from pancreas cancer who had refused
chemotherapy [122]. They were randomised to receive
either Vitamin C alone or with Ukrain (total dose 100 mg/
patient). The primary endpoint (survival) strongly
favoured the Ukrain group. The analysis seems to include
4 protocol violations (the description is unclear). Even
though the randomisation procedure is mentioned
('closed envelopes') it seems unusual that precisely 21BMC Cancer 2005, 5:69 http://www.biomedcentral.com/1471-2407/5/69
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patients ended up in both groups. The results are surpris-
ingly good – much better than with any other treatment
for that condition.
Uglyanitsa et al randomised ("by lottery") 75 breast can-
cer patients into three groups of 25 patients each [123].
They received either no specific treatment, a total dose of
50 or 100 mg Ukrain 5–7 days before mastectomy. The
authors note that Ukrain rendered the primary tumour
and the affected regional lymph nodes larger, harder and
"more clearly defined". They interpret this as Ukrain-
induced tumour sclerosis. According to the investigators'
judgement, these changes facilitated surgery and the oper-
ative success. In addition, Ukrain was associated with
remarkable symptomatic improvements, e.g. better appe-
tite, more sleep, less weakness. The report is unclear in
several respects. For instance, no details about statistical
analyses are provided, the outcome measures seem sub-
jective, no information regarding investigator blinding is
given, and the randomisation procedure seems suspect.
Zemskov and colleagues randomised 42 patients with
pancreatic cancer who had refused conventional therapy
[124]. They received either Ukrain (total dose 100 mg/
patient) with Vitamin C or Vitamin C alone. The results
confirmed this group's earlier findings [122]. Survival was
remarkable in the Ukrain treated patients and symptoms
responded well to this treatment. There are, however,
numerous puzzling details. Why do the authors call their
second study a "pilot study"? Why did their ethics com-
mittee consent to this "placebo"-controlled trial in the
knowledge of the surprisingly positive earlier results?
How could a proper randomisation again result in two
equally sized groups of 21? In the discussion, the authors
describe their earlier results as though this trial was con-
ducted against 5-FU which, in fact, is not the case [122].
Gansauge et al reported a study of 90 patients with pan-
creatic cancer treated either with 1000 mg gemcitabine/
m2 or 100 mg Ukrain or the combination of both regi-
mens [125]. Survival rates suggested that Ukrain was supe-
rior to gemcitabine alone. A direct comparison of the 12
month survival rates revealed large differences compared
to the data from Zemskov et al [124] (29% vs 76% in the
Ukrain-treated groups). The randomisation procedure
was not explained and, again, the equal group sizes are
remarkable.
Conclusion
Collectively, these RCTs seem to suggest that Ukrain is an
effective therapy for a range of cancers. In conjunction
with the numerous encouraging case reports [84-97] case
series [98-108], and non-randomised clinical trials [109-
121] these data look impressive at first glance. Yet several
important caveats need to be considered.
None of the RCTs in this systematic review is without seri-
ous methodological limitations. The Jadad score [119] of
most RCTs was low. Their sample size was usually small,
and a sample size calculation to define the number of
patients required was lacking in most cases. Even though
most RCTs were non-inferiority studies by design and pur-
pose, their statistical approach was that of a superiority
trial. The majority of RCTs were conducted in Ukrainian
research institutes and published in only two different
journals. In several trials, there are clear signs of involve-
ment of the manufacturer of Ukrain. Most RCTs have gen-
erally been poorly evaluated and reported, which possibly
reflects the poverty of clinical science in Eastern Europe.
Independent replications are not available. The only Ger-
man study [125] has also been heavily criticised: its sam-
ple size (30 patients in each group) is minute, the report
lacks statistical detail and there is an inequality of treat-
ment cycles between groups [127]. It was also noted that
this study (the only RCT not published in the same two
journals as all the other RCTs) was published in a journal
for which the senior author served as editor [127]. No
RCTs were found showing negative or near neutral results;
this might suggest the existence of publication bias for
which we did, however, find no definite proof.
Greater celandine (Chelidonium majus L), which forms the
basis of Ukrain, was traditionally used for liver and gall-
bladder complaints, loss of appetite and gastroenteritis.
None of these indications is supported by trial evidence.
The main alkaloid from this plant, chelidonine, has anti-
spasmodic, weak central analgesic and papaverine-like
effects. In animal experiments, an alcoholic extract of
greater celandine increased bile flow, caused non-specific
immune stimulation and acted as a hepatoprotectant
[128]. The oral administration of greater celandine in
humans has been associated with several cases of toxic
hepatitis [129].
The mechanism of action of Ukrain as an anticancer drug
(if any) remains elusive. Collectively, the preclinical stud-
ies are suggestive of antineoplastic and immunomodula-
tory effects. It has been postulated that the antineoplastic
effect is due to the alkaloids interfering with the metabo-
lism of cancer cells, diminished synthesis of DNA, RNA
and proteins, the inhibition of cellular oxygen consump-
tion, and the induction of programmed cell death in
malignant cells [130].
Several reports of adverse reactions after greater celandine
have been published. Most notably, toxic hepatitis has
been associated with its oral use [129,131,132]. No case
reports of adverse events have emerged of intravenous
Ukrain therapy for cancer. The clinical trial data suggest
that Ukrain might cause the following adverse effects: an
increase in patients' body temperature (n = 26)BMC Cancer 2005, 5:69 http://www.biomedcentral.com/1471-2407/5/69
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[120,123,125], general burning sensations (n = 3) [123]
and bleeding (n = 4) [125]. Levels between 0–2 according
to World Health Organisation toxicity criteria were noted
in two trials [122,124] and toxicity criteria between 0–3
were observed in one trial [125]. The costs of Ukrain ther-
apy are high; one course costs € 700 for the medication
alone, and the total treatment costs have been estimated
at € 3000 per week [133].
In conclusion, Ukrain is a plant-based anticancer drug
that is supported by clinical and pre-clinical evidence in a
range of malignancies. The data are, however, not free
from problems. Before positive recommendations can be
issued, independent replications with definite trials and
larger sample sizes seem mandatory.
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